Rocket Pharmaceuticals
RCKT
168 hedge funds and large institutions have $1.46B invested in Rocket Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 77 increasing their positions, 41 reducing their positions, and 24 closing their positions.
424% more call options, than puts
Call options by funds: $18.9M | Put options by funds: $3.6M
88% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 41
33% more capital invested
Capital invested by funds: $1.1B → $1.46B (+$362M)
29% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 24
2% more funds holding
Funds holding: 164 → 168 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8.2% less ownership
Funds ownership: 104.58% → 96.38% (-8.2%)
Top Buyers
| 1 |
RI
RTW Investments
New York
|
+$34.7M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$28.1M |
| 3 |
BlackRock
New York
|
+$20.1M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
+$15.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.4M |
Top Sellers
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$20.2M |
| 2 |
Goldman Sachs
New York
|
-$18.6M |
| 3 |
DM
Deerfield Management
New York
|
-$13.9M |
| 4 |
Morgan Stanley
New York
|
-$12.2M |
| 5 |
HM
HealthCor Management
New York
|
-$7.28M |
RCKT Hedge Fund Activity: Q4 2022 in Review
168 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2022, worth a combined $1.46B — up 33% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RCKT positions and 24 closed out — a net gain of 7 holders — while 77 added to existing stakes and 41 trimmed.
The largest buyer was RTW Investments, adding an estimated $34.7M. The largest seller was Tang Capital Management, exiting entirely with an estimated $20.2M sold.
- 168 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2022, up from 164 in Q3 2022.
- Funds reported $1.46B of Rocket Pharmaceuticals stock for Q4 2022, up 33% quarter-over-quarter.
- 31 funds opened new Rocket Pharmaceuticals positions in Q4 2022 and 24 closed out, a net change of +7 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2022 was RTW Investments, an estimated $34.7M added.
- The largest Rocket Pharmaceuticals seller in Q4 2022 was Tang Capital Management, an estimated $20.2M sold.
Based on aggregated 13F filings for Q4 2022.